1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jiangsu Bioperfectus Technologies Co. Ltd. Class A

Jiangsu Bioperfectus Technologies Co. Ltd. Class A

SSSE:688399
23.70
CNY
+0.57
(+2.46%)
3.81BMarket Cap
Jiangsu Bioperfectus Technologies Co. Ltd. Class A
SSE:688399
(Shanghai Stock Exchange)

Recent

price

23.70

P/E

ratio

- -

div

yld

0.22%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.48
1.94
2.39
2.91
13.55
22.12
43.1
3.14
2.36
2.73
- -
Revenue per Share
0.1
0.44
0.66
0.84
6.38
9.3
14.23
-2.91
-0.01
-0.33
- -
Basic EPS, GAAP
- -
0.34
-0.13
0.01
6.24
5.31
12.57
-1.75
0.56
-0.27
- -
Free Cash Flow per Basic Share
0.04
0.36
- -
- -
1.37
2.54
4.6
0.05
0.05
2.36
0.05
Dividend per Share
2.62
2.7
3.37
7.95
12.96
19.75
29.42
26.52
26.19
23.59
23.71
Book Value per Share
2.59
2.68
3.1
7.75
12.76
19.55
29.21
26.29
25.97
23.38
23.51
Tangible Book Value per Share
87
96
96
99
128
128
128
128
148
124
124
Basic Weighted Avg Shares
129
187
231
289
1,740
2,839
5,535
403
350
339
- -
Sales/Revenue/Turnover
4.3
24.17
28.27
31.51
53.98
47.83
44.45
-53.2
-10.96
-17.39
- -
Operating Margin (%)
6
10
14
17
22
41
94
79
59
56
- -
Depreciation Expense
8
43
64
84
820
1,193
1,828
-374
-2
-41
- -
Net Income, GAAP
38.29
15.89
12.53
11.56
14.72
14.27
14.53
- -
147.81
- -
- -
Effective Tax Rate (%)
6.47
22.78
27.67
29
47.11
42.03
33.03
-92.72
-0.57
-12.12
- -
Profit Margin (%)
213
203
198
796
1,249
1,683
2,777
2,346
1,771
1,227
1,233
Working Capital
- -
- -
- -
- -
8
7
11
9
7
56
87
LT Debt
252
260
324
1,021
1,664
2,536
3,778
3,405
3,251
2,929
2,944
Total Equity
- -
16.53
21.7
12.4
58.28
53.02
55.48
- -
-0.12
- -
- -
Return on Invested Capital (%)
- -
16.65
21.29
11.94
59.59
54.01
55.68
- -
-0.16
- -
- -
Return on Capital (%)
- -
16.66
21.84
12.46
61.04
56.81
57.89
-10.41
-0.06
-1.33
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
321
445
467
LT Borrowings
49
71
81
LT Finance Leases
7
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
124
124
124
Market Capitalization
5,745
4,403
3,807

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,695
1,795
1,828
Cash, Cash Equivalents & STI
1,580
1,691
1,713
Accounts Receivable, Net
39
40
40
Inventories
52
42
47
Total Current Liabilities
468
540
594
Payables & Accruals
- -
- -
- -
ST Debt
321
445
467
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.4%
-9.91%
Free Cash Flow
- -
-54.03%
-141.07%
Net Income, GAAP
- -
366.21%
1,952.18%
Sales/Revenue/Turnover
- -
9.82%
-3.02%
Total Cash Common Dividend
- -
825.16%
4,041.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
86
91
82
350
2025
92
84
- -
82
339
2026
79
69
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
-0.08
-0.02
-0.23
-0.01
2025
0.1
-0.12
- -
-0.36
-0.33
2026
0.17
-0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.02
0.02
0.01
0.05
2025
0.01
0.03
- -
0.02
2.36
2026
0.01
0.02
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) engages in the research, development, production and sale of in vitro diagnostic products, with a focus on molecular diagnostics for infectious diseases and women's and children's health; its core offerings include real-time PCR kits for pathogens such as SARS-CoV-2, influenza A/B, monkeypox, Zika, dengue, chikungunya, mycoplasma hominis, treponema pallidum, neisseria gonorrhoeae, chlamydia trachomatis, ureaplasma urealyticum, haemophilus influenzae, mycoplasma pneumoniae, legionella pneumophila, klebsiella pneumoniae, streptococcus pneumoniae, bordetella pertussis and bordetella parapertussis; HPV genotyping detection kits; nucleic acid extraction kits and systems like the SSNP-2000B, SAW-48 automated workstation and cell nucleic acid extraction kits; supporting instruments such as the STC series RT-PCR systems; rapid diagnostic kits; and in vitro testing services. The company serves medical institutions, disease control centers and independent clinical laboratories with over 700 products across more than 100 countries and regions, including subsidiaries in the UK and offices in Shanghai and internationally. Founded in 2010 and headquartered in Taizhou, Jiangsu Province, China, it listed on the Shanghai Stock Exchange's STAR Market in December 2019. Recent developments encompass expansion of its distribution network in Southeast Asia in October 2023 to enhance accessibility of infectious disease diagnostic kits; launches of new PCR kits for sexually transmitted diseases including Mycoplasma Hominis and Treponema Pallidum; advancement into point-of-care testing (POCT) and automated systems like SAW series for streamlined PCR workflows; and active participation in global events such as Medlab Middle East, ESCMID Global, ADLM and CACLP in 2025 to drive international market penetration.